These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The clinical effect of ATG and OKT3 on the treatment of refractory rejection after cadavaric kidney transplantation].
    Author: Ao J, Li Y, Xiao X, Yang W.
    Journal: Zhonghua Wai Ke Za Zhi; 1998 Sep; 36(9):542-4. PubMed ID: 11825460.
    Abstract:
    OBJECTIVE: To observe the effect of ATG and OKT3 on the treatment of refractory rejection, including acute and chronic rejection after cadaveric kidney transplantation. METHOD: 87 patients with refractory rejection after cadaveric kidney transplantation were treated by using ATG (13 patients) and OKT3 (74). A total dose of 1 000 mg for ATG group or 45 mg for OKT3 group was administered for each patient. RESULT: Two accelerating rejection and acute rejection were reversed and 7 in the ATG group, 90.00% (27/30) and 90.47% (38/42) in the OKT3 group respectively. A significant difference of total reverse rates was seen between the ATG and OKT3 groups (69.23% verse 90.28%, P < 0.05). In retransplant patients, the reverse rate of acute rejection by OKT3 was 91.67% (11/12). But OKT3 did not show any effect in patients with chronic rejection. CONCLUSION: OKT3 is better than ATG for reversing the refractory rejection, especially in retransplant patients, but it has no any effect on chronic rejection.
    [Abstract] [Full Text] [Related] [New Search]